This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Paclitaxel

Authoring team

Paclitaxel is a taxoid which is indicated in the treatment of:

  • advanced ovarian cancer which is resistant to platinum-based chemotherapy (1,2):
    • response rates of 20-35%
    • no evidence that paclitaxel prolongs life

  • breast cancer which is resistant to first line chemotherapy such as anthracyclines:
    • response rates of 30% (2)
    • paclitaxel is better than mitomycin as a second-line agent
    • however NICE concluded that paclitaxel, within its licensed indication (adjuvant treatment of node-positive breast carcinoma following anthracycline and cyclophosphamide therapy), is not recommended for the adjuvant treatment of women with early node-positive breast cancer (3)

Reference:

  1. McGuire WP et al.Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III or stage IV disease. NEJM 1996;334: 1-6.
  2. Drug & Therapeutics Bulletin. Paclitaxel and docetaxel in breast and ovarian cancer. The Consumer's association 1997; 35 (6): 43-6.
  3. NICE (September 2006). Paclitaxel for the adjuvant treatment of early node-positive breast cancer

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.